Why Pfizer and Moderna Would Profit As CDC Recommends Covid Vaccine For Toddlers
Why Many parents are concerned about the effect of the coronavirus pandemic on their children.
avatar
Precious Njoku is a Financial Writer with extensive knowledge about the stock market.
2022-06-25 11:30

In the United States, 68% of preschoolers already have the virus. This means they have to miss out on school and social gatherings with their peers. They have also passed the virus to their parents, grandparents, and siblings.

There is relief in sight. Shots for children from 6 months to 5-6 years old will begin to roll out. Late last week, two advisory panels said that the vaccines were harmless for children of that age. The panels consist of Center for Disease Control (CDC) experts and another of experts from the Food and Drug Administration (FDA).
Why Pfizer and Moderna Would Profit As CDC Recommends Covid Vaccine For Toddlers
Parents were told that they would have to choose between the Pfizer (NYSE: PFE)/BioNTech vaccine and the Moderna (NASDAQ: MRNA) vaccine. The data shows that these two vaccines are harmless for toddlers.

The question is: Will these companies profit from the rollout of vaccines for toddlers? Is this a good sign to add these companies into your portfolio as the market takes a bearish tone?

Well, looking at the past price action would help us make wise financial decisions for the future.

The Evidence From The Past

According to the People's Vaccine Alliance's data released in 2021, Pfizer, BioNTech, and Moderna profited greatly when their vaccines were approved in 2020. The data shows that they all earned about $56,000 every minute.

Due to the enormous profits from the vaccines, the three pharmaceutical companies refused to release the recipes for their vaccines. As a result, when the WHO called for pharmaceutical companies to contribute to helping the poor developing nations with free vaccines, these companies contributed less than 1% of their vaccines to the effort.

While many believe their profits are obscene, the CEOs of Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) continued to defend themselves. They said it was insane to assume that they could release the recipes for their vaccines after the effort put into developing them. They also called insane the call for vaccine companies to relinquish the intellectual property rights to existing vaccines.

The three companies received public funding of about $8 billion from the Trump administration. But they refused to heed calls to transfer their vaccine technology to developing countries. The WHO repeatedly made these call-in conversations with the CEOs of these companies, but they turned deaf ears. It was clear that the companies were putting profit before human lives.

As for Moderna, it was reported that the White House explicitly pressured the CEO, Stephane Bancel, to collaborate and cooperate with the WHO. They wanted Moderna to replicate the Moderna vaccine at its mRNA hub in South Africa for broader distribution to developing countries, especially African countries.

Even when the WHO approved the Indian vaccine, Covaxin, for distribution to developing countries, Pfizer, BioNTech, and Moderna maintained their ground. According to Anna Marriott, the Health Policy Manager for Oxfam, they must have thought that developing countries cannot develop vaccines for their citizens. However, the Covaxin vaccine made their claims unbelievable.

Pfizer recorded a profit of $41.7 billion for its vaccines in 2020. Its revenue for 2021 was $81.3 billion. As for Moderna, it reported total revenue of $18.5 billion for 2021. This was an increase of $903 million from its 2020 revenue.

These companies are manufacturing their vaccines for the sake of their shareholders. But unfortunately, the capitalistic motive has outgunned their altruistic sides.

Should You Invest in Pfizer, Moderna, or BioNTech?

If you are investing for non-financial reasons, you would be doubtful about investing in these companies. But most investments are far from being altruistic. Most investors are capitalistic in their thinking. If that is the same for you, these three stocks will rise this week as the vaccine rollout for toddlers has begun. So, the time is ripe for adding them to your portfolio.

There are more than 30 million toddlers in America. Many parents are anxious to see that their children get vaccinated against COVID-19. As a result, these stocks have a renewed opportunity to make huge gains this year. The fundamentals are right for these three companies. The signal is suitable for a buy on these stocks.


Disclaimer: I have no positions in any of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. All information should be independently verified and should not be relied upon for purposes of transacting securities or other investments. See terms for more info.

Rate this article

positive
negative
Published On
2022-06-25 11:30

avatar
About the Author
Precious Njoku is a Financial Writer with extensive knowledge about the stock market.


buy-coffee
You've read 1 article in the last year
..thank you for supporting us and for visiting our site. Unlike many other sites, The Dog of Wall Street is available for everyone to read. Our focus is to provide great content for free. Do you like what we are doing? Buy us a cup coffee. It is the fuel that keeps us going..

Levi Strauss' Bold Gambit: Is the Denim Icon's DTC Shift Enough to Weather the Storm?
Levi Strauss & Co. boasts a strong quarter with direct-to-consumer growth and innovative fashion, but can it navigate the choppy waters of the retail market?
By Alfonso | 3 months ago

Amazon's Bold Counterattack: Introducing the China-Direct Discount Section
As competition heats up, Amazon unveils a daring new strategy to offer unbeatable prices and direct shipping from China.
By Alfonso | 3 months ago

Tesla's Legal Challenges: Facing the Music on Autopilot Misrepresentation
Court ruling intensifies scrutiny on Tesla's self-driving claims.
By Alfonso | 5 months ago

Netflix's Ad-Supported Triumph: A New Era in Streaming
Surpassing 40 million users, Netflix’s ad-supported plan redefines the streaming landscape.
By Alfonso | 5 months ago

Tesla Stock (TSLA): Look Who's Back!
I’m cautiously optimistic but I’m at the point where I need to see it to believe it.
By Mike Sakuraba | 5 months ago

2 Earnings To Pay Attention to Next Week
Since big tech is the theme, you probably know what I have my eyes on for next week.
By Mike Sakuraba | 5 months ago

2 Stocks to Watch Below $10
Here are two stocks that are currently less trading in the single digits that I believe have some relative upside from their current prices.
By Mike Sakuraba | 5 months ago

Looking Ahead to Tesla's Earnings: What Can We Expect?
Is there any stock that has been more talked about than Tesla (NASDAQ: TSLA) as of late? It’s a company that is always in the spotlight but the stock is under some heavy scrutiny this year and deservedly so.
By Mike Sakuraba | 5 months ago